Cardiovascular and metabolic risk factors: How can we improve outcomes in the high-risk patient? Discussion following Dr. Grundy's presentation

被引:32
作者
Grundy, Scott M.
机构
[1] Center for Human Nutrition, Department of Clinical Nutrition, University of Texas Southwestern Medical Center, Dallas, TX
关键词
Atherosclerotic cardiovascular disease; Framingham risk score; Lipid-lowering therapy; Metabolic syndrome; Primary prevention; Secondary prevention;
D O I
10.1016/j.amjmed.2007.06.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Risk assessment algorithms, such as that used in the third Adult Treatment Panel (ATP III) of the National Cholesterol Education Program (NCEP) for treating low-density lipoprotein cholesterol, can be used to classify patients' risk for cardiovascular and metabolic problems and to determine the appropriate level of therapeutic intervention. Patients at highest risk should receive the most intensive therapy. The presence of the metabolic syndrome, a clustering of atherogenic risk factors including dyslipidemia, elevated blood pressure, elevated blood glucose, and other problems, confers additional risk for diabetes mellitus and atherosclerotic cardiovascular disease at every level of risk. Pharmacotherapy with lipid-lowering, antiplatelet, antihypertensive, or insulin-sensitizing agents to modify specific risk factors is indicated in patients at higher risk, but lifestyle change (e.g., smoking cessation, weight reduction, increased physical activity, and heart-healthy" dietary modifications) and blood pressure control can be used across all categories of risk. © 2007 Elsevier Inc. All rights reserved."
引用
收藏
页码:9 / 9
页数:1
相关论文
共 18 条
[1]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[2]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[3]   Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study [J].
Deedwania, Prakash ;
Barter, Philip ;
Carmena, Rafael ;
Fruchart, Jean-Charles ;
Grundy, Scott M. ;
Haffner, Steven ;
Kastelein, John J. P. ;
LaRosa, John C. ;
Schachner, Holly ;
Shepherd, James ;
Waters, David D. .
LANCET, 2006, 368 (9539) :919-928
[4]  
Diabetes Prevention Progam, 2005, DIABETES, V54, P1150
[5]   Metabolic syndrome: Connecting and reconciling cardiovascular and diabetes worlds [J].
Grundy, SM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (06) :1093-1100
[6]   Diabetes and coronary risk equivalency - What does it mean? [J].
Grundy, SM .
DIABETES CARE, 2006, 29 (02) :457-460
[7]   Definition of metabolic syndrome - Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition [J].
Grundy, SM ;
Brewer, HB ;
Cleeman, JI ;
Smith, SC ;
Lenfant, C .
CIRCULATION, 2004, 109 (03) :433-438
[8]   Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome [J].
Grundy, SM .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (4A) :18B-25B
[9]   Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [J].
Grundy, SM ;
Cleeman, JI ;
Merz, CNB ;
Brewer, HB ;
Clark, LT ;
Hunninghake, DB ;
Pasternak, RC ;
Smith, SC ;
Stone, NJ .
CIRCULATION, 2004, 110 (02) :227-239
[10]  
GRUNDY SM, 2006, CIRCULATION, V29, P1220